The Fort Worth Press - Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

USD -
AED 3.672504
AFN 64.999947
ALL 82.324126
AMD 360.954502
ANG 1.790403
AOA 918.000346
ARS 1543.749989
AUD 1.479279
AWG 1.8
AZN 1.698907
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.674898
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.427855
CDF 2314.999626
CHF 0.839255
CLF 0.02536
CLP 998.102442
CNY 6.67175
CNH 6.66703
COP 3316.61
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.15145
DJF 178.554905
DKK 6.780703
DOP 60.996961
DZD 136.947837
EGP 53.746403
ERN 15
ETB 164.576405
EUR 0.906897
FJD 2.280097
FKP 0.756558
GBP 0.756725
GEL 2.589744
GGP 0.756558
GHS 11.756648
GIP 0.756558
GMD 73.999911
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84575
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 330.860995
IDR 18278.7
ILS 3.21885
IMP 0.756558
INR 93.89345
IQD 1520.102326
IRR 1913737.49877
ISK 123.889854
JEP 0.756558
JMD 158.434973
JOD 0.709017
JPY 159.415987
KES 129.930041
KGS 87.435499
KHR 4119.418691
KMF 446.999696
KPW 900.00035
KRW 1333.240543
KWD 0.31144
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.826123
MMK 2099.568705
MNT 3604.028735
MOP 8.103614
MRU 40.552456
MUR 47.809799
MVR 15.402598
MWK 1738.739965
MXN 18.57305
MYR 4.092402
MZN 63.898524
NAD 16.951268
NGN 1345.469832
NIO 36.903315
NOK 9.583895
NPR 151.114437
NZD 1.81158
OMR 0.384504
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.952022
PKR 277.274459
PLN 3.99508
PYG 6223.068898
QAR 3.655265
RON 4.852499
RSD 106.666028
RUB 82.504138
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.81956
SDG 601.498022
SEK 10.0626
SGD 1.288215
SHP 0.752984
SLE 23.050158
SLL 20969.503664
SOS 573.051087
SRD 37.49007
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.886505
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392165
TTD 6.806306
TWD 32.921501
TZS 2652.574003
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25765
VUV 120.719595
WST 2.810584
XAF 594.885499
XAG 0.021034
XAU 0.00025876167
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 594.885499
XPF 108.186074
YER 236.550111
ZAR 16.91872
ZMK 9001.201274
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084149
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025

PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024

Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025

Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025

Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028

Text size:

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.

"Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in polycythemia vera and from the ANTHEM Phase 2b ulcerative colitis study of icotrokinra," said Dinesh V. Patel, Ph.D., the Company's President and CEO. "In addition, we look forward to progressing oral IL-17 peptide antagonist PN-881 in clinical studies and nominating new development candidates from the oral obesity and oral hepcidin programs this year. We are fortunate to be in a strong cash position, enabling the flexibility to progress these early-stage peptide drug candidates independently into pre-clinical and clinical proof-of-concept studies over the coming years."

2024 Key Highlights

Worldwide License and Collaboration Agreement for Rusfertide with Takeda

  • On January 31, 2024, the Company and Takeda announced a worldwide license and collaboration agreement for rusfertide (the "Takeda License and Collaboration Agreement"). The Company received an upfront cash payment of $300.0 million in April 2024 and is eligible to receive up to $330.0 million in development, regulatory, and sales milestones, for a potential deal value of up to $630.0 million, as well as an equal share of profits and losses in the U.S. and royalties on net sales outside the U.S.

  • Under the terms of the agreement, the Company has the right to opt-out of the 50:50 profit share after NDA filing. In that event, the Company would be eligible to receive opt-out fees of up to $400 million and enhanced milestones of up to $975 million, as well as royalties on worldwide net sales. Takeda would maintain full ex-U.S. rights under either scenario.

Two articles published in the New England Journal of Medicine ("NEJM") in February 2024

  • On February 7, 2024, the icotrokinra Phase 2b FRONTIER 1 trial results in adults living with moderate-to-severe plaque psoriasis were published in the NEJM.

  • On February 21, 2024, the complete Phase 2 REVIVE trial results for rusfertide, including efficacy and safety, were published in the NEJM.

S&P SmallCap 600 Index

  • The Company joined the Index on July 3, 2024.

Icotrokinra: Oral IL-23 Receptor Antagonist

  • Positive topline results for the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies1in moderate to severe plaque psoriasis, were reported in Q4 2024.

    • In the ICONIC-LEAD study, once-daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds (64.7%) of patients treated with icotrokinra achieved IGA3 scores of 0/1 (clear or almost clear skin), and 49.6% achieved PASI 90, compared to 8.3% and 4.4% on placebo, respectively. Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9% achieving PASI 90. Safety data was consistent with the Phase 2 FRONTIER 1 and 2 studies.

    • A similar proportion of patients experienced adverse events (AEs) between icotrokinra and placebo, with 49.3% and 49.1% of participants experiencing a treatment emergent adverse event (TEAE) at week 16. In addition, positive topline results from the Phase 3 ICONIC-TOTAL study showed once-daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.

Nomination of PN-881, a potential best-in-class oral peptide IL-17 antagonist development candidate; additional discovery programs announced

  • On November 21, 2024, the Company announced the nomination of PN-881 following extensive preclinical studies, including oral stability, potency, tissue distribution, and pharmacokinetics measurements, and evaluation in immunologic pharmacodynamics and preclinical efficacy models. PN-881 demonstrated in vitro blockade of IL-17 AA homodimer, FF homodimer and AF heterodimer. It demonstrated approximately 100-fold greater potency than secukinumab, and similar potency to the most potent approved antibody drugs and nanobody therapeutics currently in development.

  • The Company expects to nominate an oral development candidate in the hepcidin mechanism-based hematology program in Q4 2025, and an oral peptide-based development candidate in the metabolic/obesity program in Q2 2025.

Achievement of a $165.0 million milestone

Under the terms of the icotrokinra license and collaboration agreement with JNJ, as amended in November 2024, the Company earned a $165.0 million milestone during Q4 2024. The $165.0 million was received in January 2025.

Recent and Upcoming Milestones

Rusfertide

  • Protagonist held an in-person PV Day on February 6, 2025, in New York; a replay of the webcast is available at https://lifescievents.com/event/protagonist/.

  • The topline data for the Phase 3 VERIFY study2 in PV, which has a 32-week primary efficacy endpoint, is expected in March of 2025.

Icotrokinra

  • Topline results for the Phase 2b ANTHEM multicenter, randomized, placebo-controlled, dose-ranging study of icotrokinra for the treatment of moderately to severely active ulcerative colitis3, are expected in March 2025.

  • Topline results for the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 superiority studies4, evaluating the safety and efficacy of icotrokinra compared with both placebo and deucravacitinib in moderate to severe plaque psoriasis, are expected in Q2 2025.

  • Further details of the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies are expected to be presented at major medical conferences this year.

Discovery Programs

  • The Company expects to nominate an oral peptide-based development candidate in the obesity program in Q2 2025, and an oral development candidate in the hepcidin mechanism-based hematology program in Q4 2025.

Fourth Quarter and Full Year 2024 Financial Results

Cash, Cash Equivalents, and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2024, were $559.2 million as compared to $341.6 million in the previous year.

Three Months Ended

Twelve Months Ended

December 31,

December 31,

(in thousands, except per share amounts)

2024

2023

2024

2023

License and collaboration revenue

$

170,638

$

60,000

$

434,433

$

60,000

Research and development expense

$

34,904

$

28,899

$

138,128

$

120,161

General and administrative expense

$

8,954

$

8,052

$

43,462

$

33,491

Net income (loss)

$

131,674

$

27,335

$

275,188

$

(78,955

)

Basic earnings (loss) per share

$

2.11

$

0.45

$

4.47

$

(1.39)

Diluted earnings (loss) per share

$

1.98

$

0.44

$

4.23

$

(1.39)

Revenue: License and collaboration revenue is derived from the Company's License and Collaboration Agreement with Johnson & Johnson (JNJ), as amended in November 2024 (the "JNJ Agreement"), and its Worldwide License and Collaboration Agreement for rusfertide with Takeda which became effective in March 2024 (the "Takeda Agreement"). Total License and collaboration revenue increased by $374.4 million from $60.0 million for the year ended December 31, 2023, to $434.4 million for the year ended December 31, 2024. The increase was attributable to:

  • Revenue recorded during the year ended December 31, 2024, pursuant to the Takeda Agreement, of $269.4 million; and

  • Revenue from the JNJ Agreement which increased by $105.0 million for the year ended December 31, 2024, as compared to the prior year. The revenue reflects the achievement of non-refundable milestones of $165.0 million and $60.0 million for the years ended December 31, 2024, and 2023, respectively.

Research and Development ("R&D") Expenses: Increased by $6.0 million and $18.0 million for the fourth quarter and full year 2024, respectively, from the prior year periods. The increases were due primarily to increases in drug discovery and pre-clinical research expenses.

General and Administrative ("G&A") Expenses: Increased by $0.9 million for the three months ended December 31, 2024, from the prior year period primarily due to an increase in stock-based compensation. The increase of $10.0 million for the full year 2024 as compared to the prior year was primarily due to $4.6 million in one-time advisory and legal fees related to the Takeda Collaboration Agreement and an increase of $4.4 million in stock-based compensation and other personnel-related expenses.

Net Income (Loss): Net income was $131.7 million, or $2.11 per basic share and $1.98 per diluted share, for the fourth quarter of 2024 as compared to net income of $27.3 million, or $0.45 per basic and $0.44 per diluted share, for the fourth quarter of 2023. Net income was $275.2 million, or $4.47 per basic share and $4.23 per diluted share, for the full year 2024, as compared to a net loss of $(79.0) million, or ($1.39) per share, for the full year 2023.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to JNJ Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra and rusfertide, the timing of icotrokinra and rusfertide clinical trials, and timing of developments and announcements in our discovery programs. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Contact Information
Corey Davis Ph.D.
Investor Relations Contact - LifeSci Advisors
[email protected]
+1 212 915 2577

Virginia Amann
Media Relations Contact - ENTENTE Network of Companies
[email protected]
+1 833 500 0061 ext 1

PROTAGONIST THERAPEUTICS, INC.
Consolidated Statements of Operations
(Amounts in thousands except share and per share data)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

2024

2023

2024

2023

License and collaboration revenue

$

170,638

$

60,000

$

434,433

$

60,000

Operating expense:
Research and development (1)

34,904

28,899

138,128

120,161

General and administrative (1)

8,954

8,052

43,462

33,491

Total operating expense

43,858

36,951

181,590

153,652

Income (loss) from operations

126,780

23,049

252,843

(93,652

)

Interest income

6,853

4,242

26,315

14,898

Other income (expense), net

31

44

250

(201

)

Income (loss) before income tax expense

133,664

27,335

279,408

(78,955

)

Income tax expense

1,990

-

4,220

-

Net income (loss)

$

131,674

$

27,335

$

275,188

$

(78,955

)

Net income (loss) per share, basic

$

2.11

$

0.45

$

4.47

$

(1.39

)

Net income (loss) per share, diluted

$

1.98

$

0.44

$

4.23

$

(1.39

)

Weighted-average shares used to compute net income (loss) per share, basic

62,328,468

60,387,606

61,566,989

56,763,559

Weighted-average shares used to compute net income (loss) per share, diluted

66,406,817

61,796,205

65,077,722

56,763,559

(1) Amount includes non-cash stock-based compensation expense.

Stock-based Compensation
(In thousands)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

2024

2023

2024

2023

Research and development

$

5,322

$

3,890

$

20,919

$

17,061

General and administrative

3,771

2,711

16,635

12,232

Total stock-based compensation expense

$

9,093

$

6,601

$

37,554

$

29,293

PROTAGONIST THERAPEUTICS, INC.
Selected Consolidated Balance Sheet Data
(In thousands)

December 31,

December 31,

2024


2023

Cash, cash equivalents and marketable securities

$

559,165

$


341,617

Working capital

544,243

334,303

Total assets

744,725

357,951

Deferred revenue

30,567

-

Accumulated deficit

(340,522

)

(615,710

)

Total stockholders' equity

675,295

336,677

1 ICONIC-LEAD (NCT06095115) and ICONIC-TOTAL (NCT06095102)

2 VERIFY (NCT05210790)

3 ANTHEM (NCT06049017)

4 ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604)

SOURCE: Protagonist Therapeutics



View the original press release on ACCESS Newswire

S.Rocha--TFWP